Medical Oncology · Cullman, AL
NPI
1346261526
Since 2006
Specialty
Medical Oncology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1750 Al Highway 157
Cullman, AL, 35058
Phone (256) 255-2500
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.7M
115,281 services
Medicare patients, 2024
511
Average age 77
Drug cost, 2024
$6.0M
1,771 prescriptions
Company payments, 2025
$3,244
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Johnny Q Nacilla was code J0897 (injection, denosumab, 1 mg), 12,000 times for 89 patients. In total Johnny Q Nacilla billed 115,281 services in 90 codes, and Medicare paid $1.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-04-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 12,000 | 89 | $20.27 | $243K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,900 | 13 | $5.70 | $17K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 2,475 | 63 | $0.23 | $562 |
| J1750 Injection, iron dextran, 50 mg | Office | 2,392 | 69 | $13.64 | $33K |
| 36415 Venipuncture Blood Collection | Office | 1,168 | 421 | $8.65 | $10K |
| 85025 Blood Count | Office | 1,124 | 363 | $7.58 | $8,515 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 500 | 13 | $0.09 | $43.01 |
| 99214 Office E&M - Established | Office | 467 | 341 | $93.77 | $44K |
| 96375 Injection Administration | Office | 454 | 91 | $11.16 | $5,068 |
| 96372 Injection Administration | Office | 438 | 113 | $10.21 | $4,473 |
| 96413 Chemotherapy Administration | Office | 176 | 25 | $93.86 | $17K |
| 96365 Intravenous Infusion, Hydration | Office | 165 | 93 | $43.88 | $7,241 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 142 | 73 | $0.65 | $91.93 |
| 96367 Intravenous Infusion, Hydration | Office | 141 | 16 | $21.45 | $3,025 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 139 | 23 | $4.79 | $666 |
By year: 2022 $2.1M for 261,983 services; 2023 $2.4M for 205,725 services; 2024 $1.7M for 115,281 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,168 | 421 | $8.65 | $10K |
| 85025 Blood Count | 1,124 | 363 | $7.58 | $8,515 |
Medicare prescription drug claims, 2024
In 2024, the drug Johnny Q Nacilla prescribed most often to Medicare patients was Letrozole, with 404 prescriptions and refills. In total Johnny Q Nacilla wrote 1,771 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 404 | 995 | 102 | $12K |
| Acyclovir Generic | 106 | 121 | 17 | $1,199 |
| Jakafi Ruxolitinib Phosphate | 93 | 93 | Under 11 | $1.4M |
| Ondansetron Hcl Generic | 79 | 79 | 41 | $1,360 |
| Levothyroxine Sodium Generic | 58 | 86 | 13 | $252 |
| Imbruvica Ibrutinib | 58 | 58 | Under 11 | $866K |
| Eliquis Apixaban | 56 | 66 | Under 11 | $38K |
| Hydroxyurea Generic | 55 | 90 | 12 | $1,871 |
| Olanzapine Generic | 53 | 58 | 23 | $554 |
| Lenalidomide Generic | 50 | 50 | Under 11 | $579K |
| Revlimid Lenalidomide | 50 | 50 | Under 11 | $877K |
| Xarelto Rivaroxaban | 38 | 38 | Under 11 | $21K |
| Gabapentin Generic | 38 | 38 | Under 11 | $329 |
| Prednisone Generic | 37 | 45 | 15 | $243 |
| Tamoxifen Citrate Generic | 26 | 54 | Under 11 | $639 |
Brand drugs: 545 claims; generic drugs: 1,226 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Johnny Q Nacilla $3,244 ($3,244 in general payments such as food, travel and fees) from 39 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $447.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 20 | $447 |
| Janssen Biotech, Inc. JNJ | 15 | $393 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $326 |
| Pfizer Inc. PFE | 9 | $178 |
| Abbvie Inc. ABBV | 7 | $146 |
| Stemline Therapeutics Inc. | 5 | $137 |
| GlaxoSmithKline, LLC. GSK | 7 | $135 |
| Genentech USA, Inc. ROG.SW | 5 | $133 |
| Celgene Corporation BMY | 4 | $114 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $108 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.